Results of BCG adjuvant immunotherapy in 100 patients with epidermoid carcinoma of the head and neck
- PMID: 911030
- DOI: 10.1016/0002-9610(77)90381-6
Results of BCG adjuvant immunotherapy in 100 patients with epidermoid carcinoma of the head and neck
Abstract
One hundred patients with advanced, recurrent, or metastatic squamous cell carcinoma of the head and neck were treated with chemotherapy and BCG as adjuvant immunotherapy. The overall response rate was 35 per cent, and the median duration of response was seventeen weeks. BCG does not prolong duration of remission or survival time.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
